文献速递类风湿关节炎

不同(类风湿)关节炎表型获得并维持无DMARD缓解的可能性

The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究基于tREACH试验,比较未分化关节炎(UA)、自身抗体阴性RA(RA-)与自身抗体阳性RA(RA+)患者在2年和5年时的无DMARD缓解率(DFR)及持续无DMARD缓解率(SDFR)。结果显示RA+的DFR与SDFR最低,UA最高;基线DAS较高、ACPA阳性、较高BMI和吸烟与(S)DFR负相关。

要点

  • RA+患者的DFR与SDFR均低于RA-和UA,UA最高。
  • 基线DAS高、ACPA阳性、高BMI、吸烟与(S)DFR负相关。
  • 短症状病程(<6个月)和6个月内缓解与(S)DFR正相关。

核心结论

  • 长期临床结局在UA、RA-和RA+之间存在差异,支持将RA按上述临床表型细分并据此分层治疗,但仍需验证。

研究设计与样本

  • 基于tREACH试验(分层单盲、达标治疗策略)纳入UA(n=130)、RA-(n=176)和RA+(n=331)患者,用logistic回归比较2年和5年的(S)DFR,用Cox比例风险模型评估预测因素。

主要发现

  • 2年和5年DFR:RA+为17.2-25.7%,RA-为28.4-42.1%,UA为43.1-58.5%。
  • 2年和5年SDFR:RA+为7.6%和21.4%,RA-为20.5%和38.1%,UA为35.4%和55.4%。
  • 减量过程中22.7%患者出现复发;DFR患者中7.5%早期复发、3.4%晚期复发(DAS≥2.4)。
  • RA+较RA-和UA有更多治疗强化。

关键数值与推荐

  • DFR定义为无DMARD缓解≥6个月,SDFR定义为无DMARD缓解≥1年。
  • 早期复发定义为达到DFR后<12个月出现DAS≥2.4,晚期复发为>12个月出现DAS≥2.4。

临床怎么用

  • 可将UA、RA-与RA+作为预后分层与治疗强度决策的参考表型。
  • 对基线DAS高、ACPA阳性、高BMI或吸烟者应预期(S)DFR可能性较低。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to compare DMARD-free remission rates (DFRs) and sustained DFRs (SDFRs), defined as, respectively, DFR for ≥6 months and ≥1 year, after 2 and 5 years, between three clinical arthritis phenotypes: undifferentiated arthritis (UA), autoantibody-negative (RA-) and autoantibody-positive RA (RA+). METHODS: All UA (n = 130), RA- (n = 176) and RA+ (n = 331) patients from the tREACH trial, a stratified single-blinded trial with a treat-to-target approach, were included in the study. (S)DFR comparisons between phenotypes after 2 and 5 years were performed with logistic regression. Medication use and early and late flares (DAS ≥ 2.4), defined as at <12 months and >12 months after reaching DMARD-free remission (DFR), respectively, were also compared. Cox proportional hazard models were used to evaluate potential predictors for (S)DFR. RESULTS: Over the study periods of 2 and 5 years, less DFR was seen in RA+ (17.2-25.7%), followed by RA- (28.4-42.1%) and UA patients (43.1-58.5%). This also applied for SDFR over the 2- and 5-year periods in these three clinical arthritis phenotypes (respectively, 7.6% and 21.4%; 20.5% and 38.1%; and 35.4% and 55.4%). A flare during tapering was seen in 22.7% of patients. Of the patients in DFR, 7.5% had an early flare and 3.4% a late flare. Also, more treatment intensifications occurred in RA+ compared with RA- and UA. We found that higher baseline DAS, ACPA positivity, higher BMI and smoking were negatively associated with (S)DFR, while clinical phenotype (reference RA+), short symptom duration (<6 months) and remission within 6 months were positively associated with (S)DFR. CONCLUSION: Long-term clinical outcomes differ between UA, RA- and RA+. These data reconfirm that RA can be subdivided into the aforementioned clinical phenotypes and that treatment might be best stratified upon these phenotypes, although validation is needed. TRIAL REGISTRATION: ISRCTN, https://www.isrctn.com/, ISRCTN26791028.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Luurssen-Masurel N, van Mulligen E, Weel-Koenders AEAM, et al. The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes. Rheumatology (Oxford). 2022. PMID: 34352094. doi:10.1093/rheumatology/keab631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。